CVE:ZOM Zomedica Pharmaceuticals Corp. (ZOM.V) (ZOM) Stock Price, News & Analysis C$0.28 -0.02 (-6.56%) (As of 02/5/2020) Add Compare Share Share Stock Analysis Stock Analysis About Zomedica Pharmaceuticals Corp. (ZOM.V) Stock (CVE:ZOM) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get ZOM alerts:Sign Up Key Stats Today's RangeC$0.29▼C$0.2950-Day RangeC$0.29▼C$0.2952-Week RangeC$0.29▼C$1.50Volume4,800 shsAverage Volume2,858 shsMarket CapitalizationC$36.73 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewZomedica Pharmaceuticals Corp., a development stage veterinary diagnostic and pharmaceutical company, engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. Its lead drug product candidate is ZM-007, an oral suspension formulation of metronidazole for the treatment of acute diarrhea in small dog breeds and puppies. The company is also developing ZM-012, a tablet formulation of metronidazole targeting the treatment of acute diarrhea in dogs; ZM-006, a transdermal gel formulation of methimazole targeting hyperthyroidism in cats; and ZM-011, a transdermal gel formulation of fluoxetine for the treatment of feline behavioral disorders, such as inappropriate urination. It has a collaboration agreement with Celsee Diagnostics, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and with Seraph Biosciences, Inc. for development and commercialization of novel pathogen detection system. The company was founded in 2015 and is headquartered in Ann Arbor, Michigan.Read More… 625,000% Gain (Ad)Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here Receive ZOM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zomedica Pharmaceuticals Corp. (ZOM.V) and its competitors with MarketBeat's FREE daily newsletter. Email Address ZOM Stock News HeadlinesPhio Pharmaceuticals Corp.September 14, 2024 | wsj.comZomedica Corp. (ZOM) Q2 2024 Earnings Call TranscriptAugust 14, 2024 | seekingalpha.comSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's what that means for your money. Billionaire Wall Street investors are quietly offloading millions of shares. What do they know that you don't? It's arguably the most popular stock in the world. Now, one 50-year Wall Street legend says its day in the sun could finally be coming to an end. Last year, he warned of two stocks that went on to crash 60%.November 2, 2024 | Chaikin Analytics (Ad)Zomedica Corp. (AMEX:ZOM) Q1 2024 Earnings Call TranscriptMay 10, 2024 | msn.comZomedica Corp Ordinary Shares ZOMNovember 19, 2023 | morningstar.comZomedica Stock (AMEX:ZOM), DividendsMay 10, 2023 | benzinga.comZomedica acquires Structured Monitoring ProductsMay 8, 2023 | msn.comZomedica expands topline thanks to acquisitions and organic growthMarch 15, 2023 | seekingalpha.comSee More Headlines ZOM Stock Analysis - Frequently Asked Questions How have ZOM shares performed this year? Zomedica Pharmaceuticals Corp. (ZOM.V)'s stock was trading at C$0.29 at the start of the year. Since then, ZOM stock has increased by 0.0% and is now trading at C$0.29. View the best growth stocks for 2024 here. How do I buy shares of Zomedica Pharmaceuticals Corp. (ZOM.V)? Shares of ZOM stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. What other stocks do shareholders of Zomedica Pharmaceuticals Corp. (ZOM.V) own? Based on aggregate information from My MarketBeat watchlists, some other companies that Zomedica Pharmaceuticals Corp. (ZOM.V) investors own include Ocugen (OCGN), T2 Biosystems (TTOO), Meta Platforms (META), Bionano Genomics (BNGO), Onconova Therapeutics (ONTX), Biocept (BIOC) and Ford Motor (F). Industry, Sector and Symbol Stock ExchangeCVE SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryPharmaceutical Products Current SymbolCVE:ZOM CUSIPN/A CIKN/A Webwww.zomedica.com Phone734-369-2555FaxN/AEmployees50Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio4.91 Current Ratio15.31 Quick Ratio15.25 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowC$0.05 per share Price / Cash Flow5.38 Book ValueC$0.05 per share Price / Book5.82Miscellaneous Outstanding Shares128,872,000Free FloatN/AMarket CapC$36.73 million OptionableNot Optionable BetaN/A 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (CVE:ZOM) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredNvidia warning urgentI thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredNothing can stop this gold rallyAfter what's felt like nearly a decade of disappointing gains, gold is stronger than ever and continues to hit...Stansberry Research | SponsoredWall St. Legend: Millions of Americans About to Fall Out of the 1%Wall Street insider reveals the financial tidal wave about to knock millions of Americans out of the One Perce...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zomedica Pharmaceuticals Corp. (ZOM.V) Please log in to your account or sign up in order to add this asset to your watchlist. Share Zomedica Pharmaceuticals Corp. (ZOM.V) With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.